Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

David F. McDermott | Researchclopedia

Back to researchers

David F. McDermott

Beth Israel Deaconess Medical Center ORCID

1,056

Works

88,519

Citations

109

h-index

391

i10-index

Research Topics

Cancer Immunotherapy and Biomarkers Renal cell carcinoma treatment CAR-T cell therapy research

Affiliations

Boston College2017–2017

Broad Institute2009–2020

Hershey (United States)2016–2016

Indiana University Health2012–2012

Brigham and Women's Hospital2009–2009

Top Works

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi,Steven O’Day,et al.

201015,042 citations

Cancer Genomics and Diagnostics

Renal and related cancers

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian,F. Stephen Hodi,et al.

201212,535 citations

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Roy S. Herbst,Jean‐Charles Soria,et al.

20145,219 citations

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Julie R. Brahmer,Christina Lacchetti,et al.

20183,623 citations

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

Michael A. Postow,Jason Chesney,et al.

20152,748 citations

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

Suzanne L. Topalian,Mario Sznol,et al.

20142,198 citations

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

Daniel Y.C. Heng,Wanling Xie,et al.

20092,104 citations

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

David F. McDermott,Mahrukh Huseni,et al.

20181,229 citations

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Scott Gettinger,Leora Horn,et al.

20151,189 citations